+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Inhibitory effect of ipriflavone on vertebral bone mass loss in postmenopausal women with low bone mass



Inhibitory effect of ipriflavone on vertebral bone mass loss in postmenopausal women with low bone mass



Osteoporosis International 6(1 Suppl.): 93-93




Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 062540458

Download citation: RISBibTeXText

DOI: 10.1007/bf02499910


Related references

Ipriflavone prevents radial bone loss in postmenopausal women with low bone mass over 2 years. Osteoporosis International 7(2): 119-125, 1997

Effects of 1-year ipriflavone treatment on lumbar bone mineral density and bone metabolic markers in postmenopausal women with low bone mass. Hormone Research 51(4): 178-183, 1999

Effect of chronic treatment with ipriflavone in postmenopausal women with low bone mass. Calcified Tissue International 61(Suppl. 1): S19-S22, 1997

Vitamin D receptor gene polymorphisms, bone mass, bone loss and prevalence of vertebral fracture: differences in postmenopausal women and men. Osteoporosis International 10(3): 175-182, 1999

Effect of 3-year treatment with ipriflavone on peripheral bone mass in postmenopausal women. Osteoporosis International 6(1 Suppl.): 239-239, 1996

Effects of 1-year treatment with ipriflavone on bone in postmenopausal women with low bone mass. Calcified Tissue International 54(5): 377-380, 1994

Ipriflavone effect on prevention and treatment of postmenopausal bone mass loss. Relation to estrogen replacement therapy. Osteoporosis International 6(1 Suppl.): 235-235, 1996

Low body mass index is an important risk factor for low bone mass and increased bone loss in early postmenopausal women. Early Postmenopausal Intervention Cohort (EPIC) study group. Journal of Bone and Mineral Research 14(9): 1622-1627, 1999

Low body mass index is an important risk factor for low bone mass and increased bone loss in early postmenopausal women. Journal of Bone and Mineral Research 14(9): 1622-1627, 1999

Effect of promethazine on lumbar vertebral bone mass in postmenopausal women. Journal of Internal Medicine 234(2): 143-148, 1993

Soy isoflavones have a favorable effect on bone loss in Chinese postmenopausal women with lower bone mass: a double-blind, randomized, controlled trial. Journal of Clinical Endocrinology and Metabolism 88(10): 4740-4747, 2003

Vitamin D receptor gene polymorphisms are not related to bone turnover, rate of bone loss, and bone mass in postmenopausal women: the OFELY Study. Journal of Bone and Mineral Research 11(6): 827-834, 1996

Expression of microRNAs that regulate bone turnover in the serum of postmenopausal women with low bone mass and vertebral fractures. European Journal of Endocrinology 176(2): 169-176, 2017

Effects of ipriflavone on bone mass and bone remodeling in patients with established postmenopausal osteoporosis. Current Therapeutic Research 51(1): 82-91, 1992

Effect of clodronate on calcium-phosphatemagnesium homeostasis, bone mass and vertebral deformities in postmenopausal women. Osteoporosis International 6(1 Suppl.): 248-248, 1996